Exploring best practice governance for EU-funded health research consortia: A
qualitative study protocol for insight and ideation
Ana Renker-Darby ¹ *, Till Bärnighausen ^{1,2,3} , Christine Neumann ¹ , Raman Preet ^{4,5} , Marina
Treskova ^{1,5,6}
¹ Heidelberg Institute of Global Health (HIGH), Medical Faculty and University Hospital,
Heidelberg University, Heidelberg, Germany
² Africa Health Research Institute (AHRI), Somkhele and Durban, South Africa
³ Harvard Center for Population and Development Studies, Harvard University, Cambridge,
USA
⁴ Department of Epidemiology and Global Health, Umeå University, Sweden
⁵ Department of Public Health and Clinical Medicine, Unit of Sustainable Health, Umeå
University, Umeå, Sweden
⁶ Interdisciplinary Center for Scientific Computing (IWR), Heidelberg University, Heidelberg,
Germany
*corresponding author.

22 Email: ana.renker-darby@uni-heidelberg.de (AR)

23 Abstract

24

25 Background

26 International consortia have emerged as a common model to organise and fund large-scale, multi-disciplinary research in contemporary health and biomedical science. The diversity of 27 28 participants, size and complexity of these consortia necessitates effective governance to 29 achieve their research aims and societal impact. For health research consortia funded by the European Union, certain governance structures and processes have emerged out of 30 31 convention. However, there is limited scientific evidence to support their use, and little is 32 known about consortia participants' perspectives on how governance structures could be 33 improved to better serve the implementation of research. In this paper, we present a protocol 34 for a qualitative study to explore the perspectives of participants in European Union-funded 35 health research consortia on the value of governance structures and how they might be 36 improved.

37

38 Methods and analysis

39 We will conduct a qualitative study using in-depth interviews with participants in health 40 research consortia funded by the European Union. We will recruit participants following a 41 purposeful sampling approach, and recruitment will continue until saturation is reached. 42 During in-depth interviews, we will ask participants about how the governance of consortia is 43 structured and what is working well or poorly about those governance structures from their 44 perspective. We will draw on design thinking methods to help participants to ideate 45 improvements in governance structures. Data will be analysed using a thematic analysis 46 approach.

48 **Discussion**

- 49 Findings from this study will provide valuable evidence for developing and formulating
- 50 governance structures for health research consortia. The findings of this work may also
- 51 contribute to guidelines for consortium proposal submissions.

52 Introduction

International consortia have emerged as a common model to organize and fund large-scale, multi-disciplinary research in contemporary health and biomedical science [1, 2]. Consortia involve collaboration between several institutions, both academic and non-academic, across multiple geographic locations and with a variety of disciplinary expertise. Such consortia are usually funded for a specific purpose over a limited funding period with a fixed-term research contract [1].

59 Funding agencies are increasingly promoting multi-disciplinary project teams due to

60 increasing scientific specialization in combination with the growing need to address complex,

61 multi-faceted societal challenges such as pandemic prevention and preparedness or climate

62 change and health research [3]. International research consortia can provide wide-ranging

63 expertise and interdisciplinary collaboration to understand these complex issues, as well as

64 bringing together stakeholders across multiple geographic locations to address global

65 problems [4].

66 The scale and complexity of research consortia means that they require effective governance 67 to achieve their research aims. Governance refers to the sustained and focused attempts to 68 direct behaviour, with the intention of producing a broadly identified outcome [3]. 69 Governance comprises both the structures and processes through which decisions about 70 goals, priorities and activities are made, as well as who makes those decisions. Ultimately, 71 consortium governance should enable the project's activities to be carried out in a way that 72 balances the interests of the different partners and leads to the attainment of the consortium 73 objectives [3].

Effective governance is necessary for several reasons. First, increasing scientific
specialization and a growing need to address complex, multi-faceted challenges mean that

76 consortia often incorporate researchers from a wide range of disciplines to avoid siloed 77 approaches [3]. This diversity of backgrounds and approaches sometimes leads to challenges 78 in the collective identification of issues and solutions [4]. Research teams are also becoming 79 larger, more geographically dispersed, and include researchers from multiple institutions in 80 different countries and cities [3]. Consortia also often involve increasing numbers of public-81 private partnerships, bringing together academic institutions with non-governmental 82 organisations and commercial companies [5]. Each of these institutions often have different 83 and sometimes competing goals from the research, which need to be addressed and managed 84 during the implementation [3, 6]. Clear rules about data access, publication and patenting are 85 also required, particularly with increasingly large datasets [3, 6]. Finally, consortia 86 governance is required to ensure compliance with external regulations around data protection 87 and ethics, such as the General Data Protection Regulation [6]. As such, the governance of 88 large research consortia facilitates the implementation of the research and ensures the 89 realisation of expected outcomes and pathways to societal impact. 90 Health research consortia that are funded by the European Union (EU) have varying 91 governance structures depending on their aims, but at a high level there are certain 92 commonalities. Governance structures are partially determined by the funding body, both in 93 the requirements for submitting grant proposals and through the contractual agreement 94 between the consortium and the funder. For example, EU-funded research requires that 95 consortia are structured in work packages, each with their own milestones and deliverables. 96 Each grant agreement confirms the timelines for deliverables as well as reporting periods and 97 mechanisms [3]. Governance structures must also conform to EU policies, such as those of

98 gender equality and inclusiveness [7]. Other aspects of consortia governance structures are

99 determined by the external regulations that the consortium is bound by, including data

100 protection laws, ethics, and regulations of the various participating institutions [1, 3].

101 Other key elements of governance structures have emerged through convention. Consortia 102 typically employ modular components to coordinate the activities of partner institutions and 103 align them with the funding agency priorities [3]. These often include a management team or 104 steering committee responsible for the internal governance of the research consortia. Consortia usually also have varying external advisory bodies that provide high-level 105 106 governance for the consortium's direction. Consortia use different external advisory bodies 107 depending on their aims, but this often includes an ethics advisory board and scientific 108 committee of external experts. These explicitly defined governance structures are 109 complemented by a range of informal governance processes that are used in practice and vary 110 between consortia. 111 Participation in the governance structures of consortia often demands significant time from 112 the consortia participants. Previous qualitative interviews with consortia participants found

delay scientific work [5]. As such, it is crucial that both the governance structures and
processes of consortia support participants to implement the consortium's research activities

that consortium governance structures can create additional bureaucratic workload that can

and meet research objectives outlined in the grant agreement without creating unnecessary

117 work that can tie up participants' expertise and resources [1, 8].

113

While there is some previous empirical research on the governance of health research consortia, this has tended to focus on the power dynamics between institutions from highincome countries and low- or middle-income countries [9-13] or the development of data governance policies within health research consortia [6, 8, 14]. Further literature draws on authors' experience within consortia to explore the way that conventional governance structures can undermine scientists' ability to implement responsible research and innovation [3], or to propose principles or guidance for consortia governance [1, 4]. To our knowledge,

125	there is currently no empirical research that explores the value of governance structures from
126	the perspective of consortia participants across a range of health research consortia.
127	Further, literature on how governance structures could be improved is usually limited to
128	abstract principles or guidelines. At present, we lack research that draws on the perspectives
129	of consortia participants to ideate improvements in governance structures. Design thinking, a
130	human-centred approach for innovating solutions, offers methods for ideating concrete
131	solutions to complex problems in health research [15, 16]. Design thinking has been
132	previously employed in healthcare research, but has rarely been used in other areas of health
133	research [15]. Design thinking methods offer an innovative approach for ideating
134	improvements in consortia governance from the perspective of participants.
135	In this study, we aim to understand the perspectives of consortia participants on how the
136	governance of EU-funded health research consortia is structured, the value of governance
137	structures and processes, and how governance structures and processes could be improved.
138	
139	
140	Materials and methods
141	
142	Study design
143	This is a qualitative research study addressing four research questions:
144	1. How are the internal steering functions and external advisory functions of EU-funded
145	health research consortia commonly structured?
146	2. What is the value of the internal steering functions and external advisory functions in
147	EU-funded health research consortia from the perspective of consortia participants?

148	3. What is the value of ethics advisory boards for research in EU-funded health research
149	consortia from the perspective of consortia participants?
150	4. According to consortia participants, how can the governance of EU-funded health
151	research consortia be improved?
152	
153	This study will take place between October 2023 and July 2024. The data collection method
154	for this research is in-depth interviews with participants in EU-funded health research
155	consortia. In the interviews, we will explore the perspectives of participants on the value of
156	consortia governance structures for the implementation of research. We will also employ
157	design thinking methods to ideate improvements in consortia governance structures.
158	
159	Population
160	The study population includes participants in active EU-funded health research consortia.
161	Criteria for inclusion in the study are as follows:
162	- 18 years or older
163	- English speaking
164	- Participation in an EU-funded health research consortium that has been active for at
165	least six months
166	- Member of at least one of four participant groups: i) lead scientists/researchers
167	(overall lead, work package lead or co-lead); ii) non-lead scientists/researchers; iii)
168	non-scientists (e.g. non-governmental organisation participants); iv) project co-
169	ordinators or administrators.
170	- Agree to participate and sign the consent form
171	
172	Participants who do not meet the inclusion criteria will be excluded.

173

174 Sample size

175 A minimum of 20 participants will be interviewed, with at least five participants in each of

- the four participant groups described above and a balance of genders across participants.
- 177 Recruitment and data collection will continue alongside data analysis until data saturation has
- 178 been reached. We will use the concept of saturation as defined by Morse to determine when
- 179 data collection will end [17, 18]. Morse describes saturation as when data from several
- 180 participants have essential characteristics in common, enabling abstraction from individual
- 181 participants' data and theoretical development.

182

183 Participant recruitment and sampling

For recruitment, we will use a purposeful sampling approach that aims to select informationrich cases for in-depth study [19]. Sampling will occur on the basis of maximum variation to collect a diverse range of perspectives and ensure transferability of findings across EUfunded health research consortia [19]. To ensure diversity of participants we will apply four criteria: participant role within the consortium (lead scientists/researchers; non-lead scientists/researchers; non-scientists; project co-ordinators or administrators), gender, country of institution, and consortium.

191

The research team will initially invite at least one potential participant from each group from their own networks to participate in the study. We will provide participants with a participant information sheet and consent form via email. Participants will have the chance to read the participant information sheet and ask the research team any questions before signing the consent form and emailing it to the research team. We will then schedule an interview time with the participant.

198

Further, we will ask the participants whether they can recommend other potential participants from their own networks in any of the four groups and to prioritise participants of a different gender to their own, who work at an institution in a different country, and who participate in a consortium that the primary institution of the study investigators is not involved in. This recruitment approach will continue until saturation is reached [18].

204

205 **Data collection**

In-depth interviews will be conducted by one researcher (AR) using a semi-structured interview schedule to guide the conversation. We chose this method of data collection to collect rich, qualitative data on the subjective perspectives of participants based on their experiences in health research consortia [20]. The interview schedule was developed based on the research questions and was piloted with two of the study co-investigators. The data generated from the pilot interviews will not be incorporated into the findings of this study.

During the interview, participants will first be asked for some demographic information (gender, country, institution/organisation, position at institution, discipline) and for information about the consortium that they are part of (name, start and end date, number of partners, location of partners, the participant's role in the consortium). If the participant is a member of more than one consortium, they will be asked to choose one to focus on in the interview. Participants will then be asked to describe how the internal steering functions and external advisory functions of their consortium are structured.

220

We will use two design thinking methods to explore the value of governance structures and ideate improvements. The 'rose, bud, thorn' tool will be used to help participants identify

223 what is working about governance structures, what currently is not working, and what has 224 potential [21]. 'How might we' ideation questions will be used to shift participants from 225 insight to early-stage ideation, prompting participants to suggest ways that consortia 226 governance structures could be improved [22]. 227 228 We will conduct interviews using Zoom videoconferencing software, as participants are 229 based in a range of locations. Interviews will be audio-recorded. Recordings will be 230 transcribed and audio-recordings will be deleted as soon as transcription is complete. We will 231 return transcripts to participants for any edits they may wish to make. 232 233 **Data analysis** 234 Data will be analysed by one researcher (AR) using NVivo software. Data will be analysed 235 using the thematic analysis approach described by Braun and Clarke [20, 23]. We chose 236 thematic analysis due to its methodological flexibility and its inductive approach, enabling 237 the development of analytical themes that respond to the research questions [23]. 238 239 Data will be inductively coded, building a bank of codes. We will then arrange these codes 240 into descriptive themes. Descriptive themes will be organised into analytical themes that 241 respond to the research questions. Data analysis will be an iterative process, with codes being 242 renamed and reorganised as analysis continues and new data are collected. We will use peer 243 debriefing between co-investigators to ensure the rigour of data analysis. 244 245 **Ethics** 246 This study received ethics approval from the Ethics Committee of the Medical Faculty of 247 Heidelberg University on 13.09.2023 [reference number S-516/2023]. The study is conducted

- 248 under the General Data Protection Regulation. All participants will be provided with a
- 249 participant information sheet explaining the study and what their participation would involve.
- 250 Participants will sign an informed consent form before participating.
- 251
- 252 **Registration**
- 253 This study was registered with OSF Registries on 1.11.2023
- 254 [https://doi.org/10.17605/OSF.IO/TD6QX].
- 255

256 **Discussion**

257 The purpose of this study is to explore the perspectives of consortia participants on the

258 governance structures of EU-funded health research consortia and ideate ways that

259 governance structures can be improved. At present, there is limited evidence that supports the

260 conventionally used governance structures in health research consortia. Participation in these

261 governance structures is often bureaucratic and time-consuming for consortia participants.

262 This study will provide evidence on how the governance structures of health research

263 consortia can be improved to better serve the objectives of the consortium and the needs of

consortium participants.

265

Findings from this study can be used by researchers when setting up future health research consortia, to develop evidence-based governance structures for their consortia. Findings may also be used by the consortium that this study is part of to improve its own governance structures. Future research could build on the study findings to develop and test best practice guidelines for the governance of EU-funded health research consortia.

271

272 Study status

273 Participant recruitment is underway and data collection is expected to end in February 2024.

274 **References**

- 1. Kaye J, Muddyman D, Smee C, Kennedy K, Bell J, UK10K. 'Pop-up' governance:
- developing internal governance frameworks for consortia: the example of UK10K. Life Sci
- 277 Soc Policy. 2015;11(10):1-17.
- 278 2. Burgio MR, Ioannidis JPA, Kaminski BM, DeRycke E, Rogers S, Khury MJ, et al.
- 279 Collaborative cancer epidemiology in the 21st century: the model of cancer consortia. Cancer
- 280 Epidemiol Biomarkers Prev. 2013;22(12):2148-60.
- 281 3. Morrison M, Mourby M, Gowans H, Coy S, Kaye J. Governance of research consortia:
- 282 challenges of implementing Responsible Research and Innovation within Europe. Life Sci
- 283 Soc Policy. 2020;16(13):1-19.
- 4. Koelle B, Scodanibbio L, Vincent K, Harvey B, van Aalst M, Rigg S, et al. A guide to
- effective collaboration and learning in consortia: building resilience to rising climate risks.
- 286 London, UK: Red Cross Red Crescent Climate Centre; 2019.
- 287 5. Morrison M. "A good collaboration is based on unique contributions from each side":
- assessing the dynamics of collaboration in stem cell science. Life Sci Soc Policy.
- 289 2017;13(7):1-20.
- 290 6. Teare HJA, de Masi F, Banasik K, Barnett A, Herrgard S, Jablonka B, et al. The
- 291 governance structure for data access in the DIRECT consortium: an innovative medicines
- initiative (IMI) project. Life Sci Soc Policy. 2018;14(20):1-17.
- 293 7. European Commission. European research area policy agenda overview of actions for the
 294 period 2022-2024. Brussels; 2021.
- 8. Morrison M, Klein C, Clemann N, Collier DA, Hardy J, Heißerer B, et al. StemBANCC:
- 296 governing access to material and data in a large stem cell research consortium. Stem Cell Rev
- 297 Rep. 2015;11:681-7.

- 298 9. Pratt B, Hyder AA. Governance of transnational global health research consortia and
- 299 health equity. Am J Bioeth. 2016;16(10):29-45.
- 300 10. Tagoe N MS, Pulford S, Murunga VI, Kinyanjui S. Managing health research capacity
- 301 strengthening consortia: a systematised review of the published literature. BMJ Global
- 302 Health. 2019;4:1-12.
- 303 11. Tagoe N, Pulford J, Kinyanjui S, Molyneux S. A framework for managing health research
- 304 capacity strengthening consortia: addressing tensions and enhancing capacity outcomes. BMJ
- 305 Glob Health. 2022;7(e009472):1-28.
- 306 12. Pratt B, Hyder AA. Governance of global health research consortia: sharing sovereignty
- and resources within Future Health Systems. Soc Sci Med. 2017;174:113-21.
- 308 13. Parker M, Bull S. Ethics in collaborative global health research networks. Clin Ethics.
 309 2009;4:165-8.
- 310 14. Muenzen KD, Amendola LM, Kauffman TL, Mittendorf KF, Bensen JT, Chen F, et al.
- 311 Lessons learned and recommendations for data coordination in collaborative research: The
- 312 CSER consortium experience. HGG Adv. 2022;3(100120):1-15.
- 313 15. Oliveira M, Zancul E, Fleury AL. Design thinking as an approach for innovation in
- healthcare: systematic review and research avenues. BMJ Innov. 2020;7:491-8.
- 315 16. Brown T. Design thinking. Harv Bus Rev. 2008;Jun.
- 316 17. Morse JM. Editorial: The significant of saturation. Qual Health Res. 1995;5(2):147-9.
- 317 18. Morse JM. "Data were saturated...". Qual Health Res. 2015;25(5):587-8.
- 318 19. Patton M. Qualitative evaluation and research methods. Beverly Hills, CA: Sage; 1990.
- 319 20. Braun V, Clarke V. Successful Qualitative Research. London: Sage; 2013.
- 320 21. The Luma Institute [Internet]. A taxanomy of innovation. Harv Bus Rev [Internet]. 2014
- 321 [cited 2023 October 10]. Available from: https://hbr.org/2014/01/a-taxonomy-of-innovation.
- 322 22. IDEO.org. The field guide to human-centred design. Canada: IDEO.org; 2015.

- 323 23. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res in Psychol.
- 324 2006;3(2):77-101.